Premium
Characteristics, treatments, and prognosis of a critical illness polyneuromyopathy patient with positive anti‐GM1 after severe traumatic brain injury: A case report
Author(s) -
Luo Jiemin,
Xia Zhiyuan,
Che Yanjun,
Zhou Ke
Publication year - 2021
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13496
Subject(s) - medicine , glucocorticoid , traumatic brain injury , antibody , ganglioside , dorsum , surgery , anesthesia , immunology , anatomy , biochemistry , chemistry , psychiatry
To investigate the clinical features, treatment and prognosis of critical illness polyneuromyopathy (CIPNM) in patients with severe traumatic brain injury (sTBI) who had positive anti‐ganglioside GM1 (anti‐GM1) antibody IgG. A case of CIPNM with positive anti‐GM1 antibody IgG was retrospectively analysed and followed‐up for 30 months. After 1 week of treatment with large dose of short‐term glucocorticoid and human immunoglobulin, the muscle strength of both lower extremities was restored to grade 1. Three months later, the muscle strength and muscle tension of the patient’s limbs returned to normal except for grade 3 of bilateral dorsal extensor muscle strength. In addition, the patient can walk alone with a waddling gait. After 30 months, there was no recurrence. The application of large dose of short‐term glucocorticoid and human immunoglobulin to CIPNM that are positive for anti‐GM1 antibodies may be an effective treatment.